Arcus Biosciences: Did Gilead Sciences overpay for its latest investment? [Seeking Alpha]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
The new share purchase came priced $21/share, compared to the $15.49 that RCUS shares were trading at on the open market during Tuesday's midday action. Did GILD overpay for this additional stake in RCUS, offering a 37% premium to Monday's closing price? Investors seem skeptical of the GILD's valuation. Despite the steep premium included in the deal price, shares of RCUS barely moved on Tuesday, climbing under 2% in midday trading. This leaves a significant gap between the current market valuation and GILD's $21-per-share view. "Gilead's private investment at $21/share is a bullish bet on Arcus's anti-TIGIT asset - which is a unique cancer target, but among a few other developers like Roche," Seeking Alpha analyst Stephen Ayers, who rates RCUS as a Speculative Buy with a confidence score of 65/100, said of the deal. "The public market isn't as confident in the drug as Gilead appears to be." Ayers added that this gap in confidence creates a kind of "arbitrage opportunity," alth
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024Business Wire
- Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual MeetingBusiness Wire
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update [Yahoo! Finance]Yahoo! Finance
RCUS
Earnings
- 2/21/24 - Beat
RCUS
Sec Filings
- 4/24/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- RCUS's page on the SEC website